Session » Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I

Date: Sunday, November 13, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 850

A Multicentre Reliability Study of Laser Speckle Contrast Imaging and Thermography in Patients with Raynaud’s Phenomenon Secondary to Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 835

A Normal Pulmonary Diffusion Capacity Is Rare in Pulmonary Artery Hypertension in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 823

A Phase 2 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness in Subjects with Systemic Sclerosis with Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 833

A Small Proportion of Patients with Systemic Sclerosis with Suspected Pulmonary Hypertension Meet the Published Inclusion/Exclusion Criteria for Two Systemic Sclerosis Associated Pulmonary Arterial Hypertension Screening Algorithms– Results from a Single Center Cohort

9:00AM-11:00AM: Abstract Number: 842

Aminaphtone Treatment Increases Skin Blood Perfusion and Related Clinical Symptoms in Patients Affected By Raynaud’s Phenomenon: A Pilot Study Based on Laser Speckle Contrast Analysis

9:00AM-11:00AM: Abstract Number: 844

Bardoxolone Methyl Produces Durable Benefits in Participants with Pulmonary Arterial Hypertension: Data from an Open-Label Extension Study

9:00AM-11:00AM: Abstract Number: 830

Cardiopulmonary Disease Development in Anti-RNA Polymerase III Positive Systemic Sclerosis; Comparative Analyses from an Unselected, Prospective Patient Cohort

9:00AM-11:00AM: Abstract Number: 853

Clinical Associations of Anti-Eukaryotic Initiation Factor 2B (anti-eIF2B) Antibodies in a Large Cohort of Patients with Anti-Nuclear Antibody Negative Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 849

Collagen Formation/Degradation Neoepitopes Are Promising Biomarkers for Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 836

Comprehensive Characterization of Calcinosis in a Multicenter International Cohort of Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 845

Current Use of Off-Label Therapies in Systemic Sclerosis-Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 832

Defining Skin Ulcers in Systemic Sclerosis: A Systematic Literature Review of Skin Ulcer Definitions and a Preliminary Consensus-Based New SSc Skin Ulcer Definition

9:00AM-11:00AM: Abstract Number: 837

Development of a Skin-Specific Scleroderma Patient Reported Outcome Instrument

9:00AM-11:00AM: Abstract Number: 834

Distinctive Clinical Phenotype of Anti-Centromere Antibody Positive Diffuse Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 848

Efficacy of Prucalopride in the Treatment of Systemic Sclerosis-Related Intestinal Involvement: Results from an Open Label Cross-over Study

9:00AM-11:00AM: Abstract Number: 838

Esophageal Dysmotility and Interstitial Lung Disease in Patients with Scleroderma: A Retrospective Study

9:00AM-11:00AM: Abstract Number: 826

Exercise Echocardiography Predicts Future Development of Pulmonary Hypertension in a High-Risk Cohort of Scleroderma Patients

9:00AM-11:00AM: Abstract Number: 847

Forced Vital Capacity Predicts Lung Fibrosis Progression and Mortality in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 843

Forced Vital Capacity Predicts Outcome in Scleroderma Associated Interstitial Lung Disease with Concomitant Pulmonary Hypertension: Data from the Pharos Registry

9:00AM-11:00AM: Abstract Number: 829

High Level of Chemokine CCL2 Is Associated with Lung Fibrosis Progression and Reduced Survival in Two Independent Systemic Sclerosis Cohorts

9:00AM-11:00AM: Abstract Number: 839

Immunosuppression Does Not Prevent Severe Gastrointestinal Disease in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 831

Immunosuppression May Prevent Interstitial Lung Disease in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 825

KL-6 and Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis Related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 841

Low Nucleoside Triphosphate Pyrophosphohydrolase Activity Contributes to Pathologic Mineralization in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 824

Mycophenolate Versus Placebo for the Treatment of Systemic Sclerosis-Related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 851

Perioral Autologous FAT Transplantation Is More Effective THAN Hyaluronic Acid Filler on Scleroderma Skin Fibrosis: Results from a LONG TERM Controlled Study

9:00AM-11:00AM: Abstract Number: 846

Progression of Left Ventricular Myocardial Dysfunction in Systemic Sclerosis: Using Speckle Tracking Strain Echocardiography to Identify Patients at Risk

9:00AM-11:00AM: Abstract Number: 822

Pulmonary Fibrosis in Mixed Connective Tissue Disease – Results from an Unselected Longitudinal Cohort

9:00AM-11:00AM: Abstract Number: 827

Severe Gastrointestinal Disease in Early Systemic Sclerosis Is Associated with an Increased Risk of Mortality

9:00AM-11:00AM: Abstract Number: 828

Survival and Health-Related Quality of Life in Incident Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Multicentre Australian Cohort Study

9:00AM-11:00AM: Abstract Number: 852

Targeting Fibroblastoid-like Cells By Drug Loaded Engineered Gold Nanoparticles As a Novel Approach for ILD-SSc Treatment

9:00AM-11:00AM: Abstract Number: 854

The Ducas: Proposal for a Digital Ulcer Assessment Score in Scleroderma

9:00AM-11:00AM: Abstract Number: 855

The Relationship Between Systemic Sclerosis and Breast Cancer and the Effects on Treatment Outcome

9:00AM-11:00AM: Abstract Number: 840

Time Trends in Incidence and Mortality of Systemic Sclerosis in Denmark from 1995-2011: A Nationwide Cohort Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].